



March 25, 2020

To our valued partners,

As the coronavirus (COVID-19) continues to affect communities in the U.S. and around the world, our hearts go out to those impacted. We are operating with a high degree of care as we protect our employees and customers during this public health crisis. During these uncertain and rapidly-changing times, we know you also have been actively working to support your members who are some of the highest risk members of our communities.

We believe it is our responsibility to prioritize two things:

- our commitment to supporting the health and safety of our employees, customers and patients and
- protecting our ability to manufacture and supply medicines, vaccines and consumer products for patients.

Consistent with our values and role as a science-led global healthcare company, we will continue to make decisions informed by the latest science and in consultation with leading health authorities. We are implementing a variety of measures to ensure the health and well-being of our customers, our employees and our communities.

Ensuring medicine supply and access. At this time, there is no impact on our ability to make our medicines, vaccines and consumer healthcare products. As this is a dynamic situation, we are continuing to monitor all parts of our supply chains closely and proactively assessing existing contingency plans which might be required, should the situation persist or worsen. We are experiencing an increase in demand for some of our respiratory products and we are actively managing supply.

Caring for our people and communities. We are taking several measures to protect the well-being of our employees and the communities in which we operate. We are moving to virtual interaction approaches to support our customers and ensure adequate supply and access to resources such as samples and planned educational programs as appropriate.

Contributing to the fight against COVID-19. GSK is using our science, technology and portfolio to support development of products for prevention/treatment of COVID-19. As the world's largest vaccines maker, we're also working with key partners to identify ways of preventing the virus.

GSK is donating \$10 million to The COVID-19 Solidarity Response Fund, created by the UN Foundation and WHO, to support WHO and partners to prevent, detect, and manage the pandemic, particularly where the needs are the greatest.

To learn more about our actions to support the global response to COVID-19, visit our [COVID-19 Resource Center](#).

Ready to help. For questions or concerns, about GSK products, vaccines, and/or product availability, please contact the [GSK Response Center](#) at 1-888-825-5249.

The situation is changing rapidly, and we are closely monitoring this as we seek to safeguard the health and wellbeing of all of our employees, limit the spread of the disease and continue to make our products available to the patients and consumers that need them. We will continue our vigilance in assessing the situation and will provide you with further updates as needed.

More than ever, know we are absolutely committed to partnering with you to provide support to ensure patients continue to receive the care they need.

Sincerely,

A handwritten signature in black ink, appearing to read "Maya Martinez-Davis".

Maya Martinez-Davis
President, U.S. Pharmaceuticals

A handwritten signature in black ink, appearing to read "Karin E. Rosén".

Karin E. Rosén, MD. PhD
Senior Vice President, US Medical Affairs